2025 Brand Name Annual Report - EMA Edition
2025 EMA Brand Name Trends
Insights from EMA-approved proprietary names on similarity risk, linguistic review, and approval outcomes
Why This Matters
EMA brand name approval is not a box-checking exercise.
Linguistic risk, cross-market clarity, and patient safety all play a critical role.
Each year, Brandsymbol analyzes EMA-approved proprietary names to identify real-world patterns in name construction, similarity exposure, and regulatory outcomes across Europe.
The 2025 EMA Brand Name Annual Report examines approved names to help global teams make stronger naming decisions earlier in development.
Key Insights from EMA Approvals
Naming Do’s and Don’ts
Do
- Evaluate names across multiple European languages early
- Treat similarity tools as directional, not determinative
- Consider spoken, written, and accented use cases
- Build broader name lists to accommodate regional risk
Don't
- Rely on a single similarity score or language screen
- Assume FDA approval guarantees EMA success
- Underestimate phonetic risk across markets
- Wait until late stages to address linguistic issues
Download the Report
Access the Brandsymbol 2025 EMA Brand Name Annual Report to understand how EMA-approved names perform under linguistic, similarity, and regulatory review and how to apply those lessons to your global naming programs.